If You Had Bought Enzychem Lifesciences (KOSDAQ:183490) Shares A Year Ago You'd Have Earned 43% Returns

While Enzychem Lifesciences Corporation (KOSDAQ:183490) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 18% in the last quarter. But at least the stock is up over the last year. However, its return of 43% does fall short of the market return of, 47%.

Check out our latest analysis for Enzychem Lifesciences

Given that Enzychem Lifesciences didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In the last year Enzychem Lifesciences saw its revenue shrink by 0.3%. Given the revenue reduction the modest 43% share price rise over the year seems pretty decent. We'd want to see progress to profitability before getting too interested in this stock.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

While the market return was 47% in the last year, Enzychem Lifesciences returned 43% to shareholders. Shareholders can take comfort that it's certainly better than the yearly loss of about 0.7% per year endured over the last three years. The optimist would say that this might be the dawn of a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 3 warning signs we've spotted with Enzychem Lifesciences (including 1 which is potentially serious) .

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on KR exchanges.

If you decide to trade Enzychem Lifesciences, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.